Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-07-18
2010-06-29
Chernyshev, Olga N (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C436S501000, C436S503000, C436S504000
Reexamination Certificate
active
07745127
ABSTRACT:
The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.
REFERENCES:
patent: 2004/0014142 (2004-01-01), VanMechelen et al.
patent: 2004/0072261 (2004-04-01), Kostanjevecki et al.
patent: 2005/0176078 (2005-08-01), Allsop et al.
patent: WO 99/50300 (1999-10-01), None
patent: WO 03/069332 (2003-08-01), None
patent: WO 2005/045034 (2005-05-01), None
Choi et al., 2004, J. Biol. Chem., vol. 279, No. 13, pp. 13256-13264.
Ardley et al., UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease, Journal of Neurochemistry, 2004, pp. 379-391, vol. 90.
Chung et al., Abstract, The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders, Trends in Neurosciences, Nov. 2001, pp. S7-S14, vol. 24, No. 11 Suppl.
Lowe et al., Abstract. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases, Journal of Pathology, Jun. 1990, pp. 153-160, vol. 161(2), Great Britain.
Nishikawa et al., Abstract, Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants, Biochemical and Biophysical Research Communications, Apr. 25, 2003, pp. 176-183, vol. 304, No. 1.
Pirim, I, Abstract, Production of anti-polyubiquitin and anti-ubiquitin carboxyl terminal hydrolase antibodies and immunohistochemically assessment of them on brain sections of Alzheimer's disease and Lewy body disease, International Journal of Neuroscience, Jul. 1998, pp. 33-42, vol. 95, No. 1-2, USA.
Rampello et al., Abstract, Dementia with Lewy bodies: a review, Archives of Gerontology and Geriatrics, Jul. 2004, pp. 1-14, vol. 39, No. 1.
Vaughan et al., Genetics of Parkinsonism: a review, Annals of Human Genetics, Mar. 2001, pp. 111-126, vol. 65, No. 2.
Von Bohlen Und Halbach et al., Abstract, Genes, proteins, and neurotoxins involved in Parkinson's disease, Progress in Neurobiology, Jun. 2004, pp. 151-177, vol. 73, No. 3.
Choi et al., Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases, The Journal of Biological Chemistry, Mar. 26, 2004, pp. 13256-13264, vol. 279, No. 13, USA.
Saigoh et al., Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice, Nature America Inc., Sep. 1999, pp. 47-51, vol. 23.
Long et al., Stimulation of the murine Uchl1 gene promoter by the B-Myb transcription factor, Lung Cancer, 2003, pp. 9-21, vol. 42.
McNaught et al., Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures, Journal of Neurochemistry, 2002, pp. 301-306, vol. 81.
Liu et al., The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect alpha-Synuclein Degradation and Parkinson's Disease Susceptibility, Cell, 2002, pp. 209-218, vol. 111.
Ardley et al., UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease, Journal of Neurochemistry, 2004, pp. 379-391, vol. 90.
MacDonald et al., Gadzooks! Nature genetics, Sep. 1999, pp. 10-11, vol. 23.
Leroy et al., The ubiquitin pathway in Parkinson's disease, Nature, Oct. 1, 1998, vol. 395.
Tran et al., Aggregates in neurodegenerative disease: crowds and power? TINS, 1999, pp. 194-197, vol. 22, No. 5.
Hashimoto et al., Transgenic Models of alpha-Synuclein Pathology, Past, Present, and Future, Annals New York Academy of Sciences, 2003, pp. 171-188.
Mermerian et al., Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors, Bioorganic & Medicinal Chemistry Letters, 2007, pp. 3729-3732, vol. 17.
Lansbury Jr, P.T., Improving Synaptic Function in a Mouse Mode of AD, Cell, 2006, Aug. 25, 2006, pp. 655-657, vol. 126.
Bifsha et al., Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway, Cell Death and Differentiation, 2007, pp. 511-523, vol. 14.
Gong et al., Ubiquitin Hydrolase Uch-L1 Rescues Beta-Amyloid-Induced Decreases in Synaptic Function and Contextual Memory, Cell, Aug. 25, 2006, pp. 775-788, vol. 126.
Hutter et al., Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease, European Journal of Neurology, 2008, pp. 134-139, vol. 15.
Healy et al., Abstract, UCHL-1 is not a Parkinson's disease susceptibility gene, Ann Neurol., Apr. 2006, pp. 627-633, vol. 59, No. 4.
Mohammad et al., Abstract, Byostatin 1 induces ubiquitin COOH-terminal hydolase in acute lymphoblastic leukemia cells, Enzyme Protein, 1996, pp. 262-272, vol. 49, No. 5-6.
Aigner et al., Abstract, Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo, Oncogene, 2002, pp. 5733-5742, vol. 21, No. 37.
Redlined Set of Claims submitted in European copending case (EP05766758.6), Mar. 11, 2009.
U.S. Appl. No. 12/214,522, filed Jun. 18, 2008 Arjol et al. Method for the Analysis of Differential Expression in Colorectal Cancer.
U.S. Appl. No. 12/308,808, filed Dec. 19, 2008 Schwartz Navarro et al. Prognostic Methods in Colorectal Cancer.
U.S. Appl. No. 12/225,008, filed Feb. 19, 2009 Maes et al. Method for Analysing Nucleic Acids.
Ballard et al., Abstract, Simple Standardised Neuropsychological Assessments Aid in the Differential Diagnosis of Dementia with Lewy Bodies from Alzheimer's Disease and Vascular Dementia, Dement Geriatr Cogn Disord, 1999, pp. 104-108, vol. 10.
Barrachina et al., Abstract, Amyloid-β deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AβPP mRNA isoforms containing the Kunitz protease inhibitor, Neurochemistry International, Feb. 2005, pp. 253-260, vol. 46, No. 3.
Iwanaga et al., Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases, Neurology, 1999, pp. 1269, vol. 52.
McKeith et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop, Neurology, 1996, pp. 1113-1124, vol. 47.
Taki et al., Significance of123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease, Annals of Nuclear Medicine, 2004, pp. 453-461, vol. 18, No. 6.
Abizanda Isidro Ferrer
Arjol Carlos Buesa
Castillo Marta Barrachina
Maes Tamara
Chernyshev Olga N
Oryzon Genomics, S.A.
TraskBritt
LandOfFree
Molecular diagnostic method for dementia with lewy bodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular diagnostic method for dementia with lewy bodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular diagnostic method for dementia with lewy bodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183559